Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma
Mission
We invest in and build companies with pioneering pharmaceutical and biotech projects or adjacent capabilities. We differentiate ourselves by using our network, expertise and resources to achieve long-term success for our companies. We have the utmost respect for all our stakeholders and strive to be described by them as a great partner.
Latest Portfolio Company News
Latest Press Releases
Interim report Q3 2024
The interim report for the third quarter 2024 was published on Wednesday October 16 at 08:00 CEST.
Presentation: the same day at 14:00 CEST.